The research driven pharmaceutical company Boehringer Ingelheim is establishing a new 50 million-plus euro pilot plant facility for the production of newly developed active pharmaceutical ingredients. The company today announced this remarkable investment in its largest research and development site worldwide in Biberach, Germany. With the construction of the new facility, Boehringer Ingelheim is ensuring that the substances from the well-stocked “research pipeline” – in other words, the supply of innovative compounds – are available for clinical studies in sufficient amounts. “In order to continue offering new products in therapeutic areas with significant unmet medical needs, such as diabetes, cancer, hepatitis C, idiopathic pulmonary fibrosis and asthma, we need to invest now”, explained Professor Andreas Barner, Chairman of the Board of Managing Directors, at the ceremony for the laying of the foundation stone in Biberach. The new technical centre is scheduled for completion in early 2014.
In the research and development process for new pharmaceutical products, the required amount of a new active ingredient grows steadily as progress is made. Whilst substance amounts measured in milligrams are sufficient during the early phases of research, the need for toxicological and pharmaceutical tests means that the amounts needed rise significantly to the two- or three-digit kilogram range in later stages. With 15 chemical reactors with volumes of 100 to 300 litres, the new pilot facility in Biberach will have the capacity to provide these substance amounts.